Harrow, Inc.

HROW Healthcare Drug Manufacturers Specialty & Generic

Harrow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $272.3 million, up 36.4% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS fell 428.6%, free cash flow fell 838.8% and total debt rose 659.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

27.28 1.47 −5.11%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
134×
Dividend yield
—
F-score
6/9
Altman Z
3.84
Beneish M
−3.04
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
5.76 4.89 6.61 7.16
P/FCF ratio
0.00 0.00 42.12 0.00
P/Operating CF
(162.61) (145.99) 214.16 107.89
P/B ratio
106.86 46.30 34.58 38.35
EV/Sales
6.53 5.64 7.25 7.85
EV/EBITDA
84.00 34.86 36.42 37.55
EV/FCF
(137.49) (389.33) 46.20 (95.18)
Current Ratio
2.24 2.48 2.20 2.72
Net Debt/EBITDA
(47.14) (12.45) 8.14 8.12
Debt/Equity
19.70 10.30 4.67 5.21
Earnings Yield
(2.33%) (1.11%) (0.31%) (0.29%)
Free Cash Flow Yield
(0.82%) (0.30%) 2.37% (1.15%)
Free Cash Flow per Share
(0.28) (0.73) 0.22 0.44
Book value per Share
0.40 0.76 1.42 1.26
Free Cash Flow
(10.29) (27.19) 8.04 16.36
EV/EBIT
0.00 76.99 64.74 70.52
Other line items

Show all line items

Columns are period end dates